Safety of AMD070 When Administered Alone or Boosted With Low-Dose Ritonavir in HIV Uninfected Men
Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
Participant gender:
Summary
Most currently approved anti-HIV drugs work by stopping the replication of HIV after it has
entered cells. AMD070 (also known as AMD11070) is designed to block HIV from entering cells
and may be effective in treating patients who have developed resistance to or are unable to
take other anti-HIV drugs. This study will evaluate the safety of different doses of AMD070
along with AMD070 boosted with ritonavir (RTV) in HIV uninfected men.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)